Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus without systemic activity

Autores organización

• Omar Javier Calixto Castaño

  Autor

• Maria Consuelo Romero Sanchez

  Autor

Autores

• Poveda S
• Meneses-Toro MA
• Vera-Parra EC
• Guzman Molano LF
• Bello-Gualtero JM

Grupos de investigación

• Grupo de Inmunología celular y molecular Universidad El Bosque (InmuBo)

  Investigador

  Maria Consuelo Romero Sanchez

Resumen

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an uncommon subtype of peripheral neuropathy, especially in systemic lupus erythematosus (SLE). We report a case of SLE presenting with CIDP successfully treated. The patient presented with bilateral, progressive, ascending, sensory, and motor neuropathy. Electrodiagnostic tests reported active motor and sensitive demyelinating polyneuropathy, and the diagnosis of CIDP was confirmed according to the European Federation of Neurological Societies/Peripheral Nerve Society criteria. Initial management with intravenous immunoglobulin and high-dose steroids was administered, then 6-month intravenous cyclophosphamide was initiated with improvement according to clinical scales. In conclusion, CIDP in SLE is rare, reported in just 0.2%. Immunosuppressive therapy should be considered whether initial improvement is not evidenced, as seen in our case requiring cyclophosphamide; interestingly, systemic activity was in remission as the peripheral nervous system is not part of neurological compromise, and we suggest evaluating this unusual presentation into rheumatological practice. © The Author(s) 2023.

Keywords

• Cyclophosphamide; Humans; Immunoglobulins, Intravenous; Lupus Erythematosus, Systemic; Peripheral Nervous System; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; antinuclear antibody; beta2 glycoprotein 1 antibody; C reactive protein; cardiolipin antibody; cyclophosphamide; hydroxychloroquine; immunoglobulin; immunoglobulin G; mycophenolate mofetil; Ro antibody; steroid; cyclophosphamide; immunoglobulin; adult; Article; case report; chronic inflammatory demyelinating polyradiculoneuropathy; clinical article; clinical outcome; disability; disease activity; electrodiagnosis; erythrocyte sedimentation rate; human; immunosuppressive treatment; kidney failure; laboratory test; lupus erythematosus nephritis; male; motor neuropathy; muscle weakness; physical examination; remission; sensory neuropathy; SLEDAI; steroid therapy; systemic lupus erythematosus; chronic inflammatory demyelinating polyradiculoneuropathy; complication; peripheral nervous system; systemic lupus erythematosu